Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Whitehawk Therapeutics (WHWK) Gross Profit (2021 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed Gross Profit for 5 consecutive years, with $6.4 million as the latest value for Q1 2025.

  • On a quarterly basis, Gross Profit rose 35.82% to $6.4 million in Q1 2025 year-over-year; TTM through Sep 2025 was $12.8 million, a 41.42% decrease, with the full-year FY2024 number at $23.0 million, up 6.56% from a year prior.
  • Gross Profit was $6.4 million for Q1 2025 at Whitehawk Therapeutics, down from $6.4 million in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $14.0 million in Q4 2021 to a low of $2.1 million in Q1 2022.
  • A 5-year average of $5.6 million and a median of $5.4 million in 2023 define the central range for Gross Profit.
  • Peak YoY movement for Gross Profit: plummeted 64.25% in 2022, then soared 150.85% in 2023.
  • Whitehawk Therapeutics' Gross Profit stood at $14.0 million in 2021, then tumbled by 64.25% to $5.0 million in 2022, then increased by 7.87% to $5.4 million in 2023, then rose by 19.45% to $6.4 million in 2024, then dropped by 0.99% to $6.4 million in 2025.
  • Per Business Quant, the three most recent readings for WHWK's Gross Profit are $6.4 million (Q1 2025), $6.4 million (Q4 2024), and $6.4 million (Q3 2024).